The ROSE Scale-up Study: Preventing Postpartum Depression
This study is looking at a program called ROSE (Reach Out, Stay Strong, Essentials for mothers of newborns) to see if it can prevent postpartum depression (PPD) in a wider group of women. ROSE is a program with five sessions that has been shown to prevent about half of PPD cases in women who are at risk. The study will compare ROSE to the usual care women receive, which typically involves screening for PPD after it has already happened. Researchers want to see if offering ROSE to all women, not just those at high risk, is a good idea. You might be able to join if you are 18 or older, 12-32 weeks pregnant, speak English, and have access to a phone. The main goal is to see if ROSE helps prevent major depressive episodes up to six months after birth. The study aims to include 2320 women.
- Study design
- This is an interventional study comparing the ROSE program to enhanced usual care. It plans to enroll 2320 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for major depressive episodes through six months after birth.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The ROSE Scale-up Study: Informing a Decision About ROSE as Universal PPD Prevention
At a glance
Conditions
NCT05700760
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Michigan State University
Flint, Michiganstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Jennifer E Johnson, PhD · PRINCIPAL_INVESTIGATOR · Michigan State University
- Caron Zlotnick, PhD · PRINCIPAL_INVESTIGATOR · Butler Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- SCID-5 Major Depressive Episodethrough 6 months after birth
The SCID is the gold standard diagnostic assessment of major depressive episode.